Skip to content

    Clean Science

    CLEANGood
    Chemicals·7 Nov 2024
    Management Summary

    Clean Science reported a strong Q2 FY25, marked by significant volume-led sales growth and stable EBITDA margins. The company is aggressively expanding its HALS product portfolio and advancing new product commercialization in pharma intermediates and performance chemicals. Despite facing raw material price increases, management prioritized volume growth and remains optimistic about achieving substantial revenue growth in the coming years through strategic capex and enhanced operational efficiencies.

    Highlights

    8
    • EBITDA remained steady at INR95 crores, with strong EBITDA margins of 42% in Q2 FY25.

    • YoY sales improved by 26%, primarily volume-led, contributing to a 25% EBITDA growth.

    • The company reported 30% overall growth for the current quarter.

    • HALS monthly sales volume scaled to 135 tons, with a target of 2,000 tons in calendar year 2025.

    • INR155 crores capex incurred in H1 FY25, primarily towards subsidiary expansion.

    • Pharma intermediate launch is on track for Q3 FY25, with revenues expected from Q4 FY25.

    • New Performance Chemicals segment construction commenced, expected to commercialize by H2 FY26.

    • Parent company capacity utilization stands at 70%, providing headroom for growth.

    Key financials

    Single quarter

    08 metrics
    1. 01EBITDA₹95 Cr+25%YoY
    2. 02EBITDA Margin42%0%QoQ
    3. 03Sales Growth26%
    4. 04Company Growth30%
    5. 05HALS Monthly Sales Volume135 tons

    Segment breakdown

    Performance Chemicals
    69% Revenue Contribution
    Pharma and Agro
    18% Revenue Contribution
    FMCG Chemicals
    14% Revenue Contribution
    List

    Guidance & targets

    15
    CategoryTargetPriority
    New Product Launch
    Pharma Intermediate Commercialization
    Q3 FY25
    High
    New Product Launch
    New Performance Chemicals Commercialization
    H2 FY26
    High
    New Product Launch
    Water Treatment Product Commercialization
    December Calendar '25
    High
    Revenue
    Pharma Intermediate Revenue Potential
    INR80-90 crores
    High
    Revenue
    Water Treatment Product Revenue Potential
    INR300-320 crores
    High
    Capex
    New Performance Chemicals Capex
    INR150 crores
    High
    Capex
    New Performance Chemicals Start Date
    June-July '25
    High
    Capex
    Total Capex for Two New Products
    INR300 crores
    High
    Capex
    Consolidated Capex (FY25)
    INR130 crores
    High
    Capex
    Consolidated Capex (FY26)
    INR200 crores
    High
    Volume
    HALS Volume
    2,000 tons
    High
    Profitability
    Subsidiary EBITDA
    Neutral/Breakeven
    High
    Margin
    HALS EBITDA Margin (Optimal Utilization)
    25%
    High
    Margin
    Parent Company EBITDA Margin
    40%+
    High
    Revenue Growth
    Long-Term Revenue Growth
    2.5x current revenues
    Medium

    Risks & concerns

    5
    RiskSeverity

    Raw Material Price Volatility and Pass-Through Challenges

    Increased raw material prices due to geopolitical events could not be fully passed on to customers, leading to gross margin compression as the company prioritized volume growth.Management acknowledged

    medium

    Competitive Pressure in HALS Segment

    Chinese competitors have scaled up capacities, driving down prices and requiring Clean Science to maintain competitive pricing, impacting realizations.Management acknowledged

    medium

    Customer Approval Timelines for New Products

    New pharma intermediate and performance chemicals require commercial product samples for customer validation, which can take 1-5 months, potentially delaying revenue ramp-up post-commercialization.Management acknowledged

    low

    Areas of Evasion(2)

    • Specific margin numbers for new Performance Chemicals beyond 'better than HALS'
    • Very long-term HALS volume targets beyond calendar year 2025

    Q&A highlights

    3

    “the raw material prices have increased over the past few months due to the war scenarios... However, we have not been able to increase or pass the price increase right now to the customer. We are right now focusing on getting the volumes back compared to last year. That is one. Second, our product mix is also changing... And hence, there is a little compression in the margins.”

    This question directly addressed the quarter-on-quarter dip in gross margins, revealing management's strategy to prioritize volume growth and customer stickiness over immediate price pass-through, alongside the impact of a changing product mix.

    asked by Sanjesh Jain

    2 min read6 chapters

    Detailed Narrative

    01

    Robust Q2 FY25 Performance Driven by Volume Growth

    Clean Science delivered a strong Q2 FY25, with sales improving by 26% year-on-year, primarily volume-led across all segments. EBITDA remained stable quarter-on-quarter at INR95 crores, maintaining a healthy EBITDA margin of 42%. The company reported an overall growth of 30% for the quarter, reflecting positive business momentum and an encouraging market environment.

    02

    Gross Margin Compression Amidst Raw Material Headwinds

    The company experienced a 250 basis points dip in gross profit margins quarter-on-quarter. This was attributed to an increase in raw material prices, particularly influenced by global geopolitical events. Management opted not to fully pass on these price increases to customers, prioritizing volume retention and market share. Additionally, a shift in product mix, with newer products like pharma intermediates and TBHQ gaining traction, contributed to the margin compression.

    03

    HALS Segment Expansion and Ambitious Volume Targets

    The HALS segment showed significant progress, with monthly sales volume reaching 135 tons. All four commonly used HALS products (701, 770, 622, 944, 119) are now successfully launched, with approvals and sales commencing for newer offerings. Management expressed high confidence in achieving a HALS volume target of 2,000 tons in calendar year 2025, supported by a complete product basket and expanding global distribution. At optimal utilization, HALS is projected to achieve an EBITDA margin of approximately 25% with an average realization of $6 per unit.

    04

    Strategic Capex for New Product Commercialization

    Clean Science incurred INR155 crores in capex during H1 FY25, primarily directed towards its subsidiary. A pharma intermediate product, with an estimated capex of INR30 crores and a revenue potential of INR80-90 crores, is on track for launch in Q3 FY25, with revenues expected from Q4 FY25. Furthermore, the company has commenced construction for two new projects: a Performance Chemicals segment (INR150 crores capex, commercializing by June-July 2025) and a water treatment product (another INR150 crores capex, commercializing by December 2025) with a revenue potential of INR300-320 crores.

    05

    Operational Efficiency and Capacity Utilization

    The parent company is currently operating at 70% capacity utilization, providing ample bandwidth for future growth without immediate capacity additions. Management anticipates that increased HALS volumes and overall capacity utilization will lead to improved yield efficiencies and a more favorable fixed cost distribution per kg, thereby enhancing gross margins. The utilization rate for TBHQ has also seen an increase to 70% in Q2 FY25.

    06

    Optimistic Long-Term Growth Outlook

    Management conveyed an optimistic outlook for long-term growth, projecting the company's revenue to reach 2.5 times its current levels within the next three years. This ambitious target is underpinned by the company's robust R&D capabilities, which have facilitated the execution of its largest-ever capex plan of approximately INR650 crores over a 2-3 year period, focusing on continuous product innovation and market expansion.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.